Other data show that if any hormonal changes occur with erythropoietin therapy in patients with CKD, these include an increase in the plasma levels of testosterone, a decrease in levels of FSH and LH, and normalization of prolactin and FSH levels [8]. This evidence concerns the gene EPO and chronic kidney disease.